Milestone’s etripamil nasal spray enters Phase III trial for atrial fibrillation

Phase 3etripamil nasal sprayPositive

AI Analysis

Summary

Milestone Pharmaceuticals has initiated a pivotal Phase III trial evaluating etripamil nasal spray for the treatment of atrial fibrillation with rapid ventricular rate (AFib-RVR).

Clinical Trial Data

Phase

Phase III

Importance:6/10

Sentiment:

0.40

Phase III trialetripamilatrial fibrillationnasal sprayAFib-RVR

Related Companies

$TRAX $ARNA

Read the original article

Published by Clinical Trials Arena on August 24, 2026 9:52 AM

Read Original